Longitudinal serologic and viral testing post–SARS-CoV-2 infection and post-receipt of mRNA COVID-19 vaccine in a nursing home cohort—Georgia, October 2020‒April 2021

Antibody titer
DOI: 10.1371/journal.pone.0275718 Publication Date: 2022-10-27T13:28:27Z
ABSTRACT
There are limited data describing SARS-CoV-2-specific immune responses and their durability following infection vaccination in nursing home residents. We conducted a prospective longitudinal evaluation of 11 consenting SARS-CoV-2-positive residents to evaluate the quantitative titers binding antibodies detected after SARS-CoV-2 subsequent COVID-19 vaccination. The included nine visits over 150 days from October 25, 2020, through April 1, 2021. Visits questionnaire administration, blood collection for serology, paired anterior nasal specimen testing by BinaxNOW™ Ag Card (BinaxNOW), reverse transcription polymerase chain reaction (RT-PCR), viral culture. evaluated post-infection post-vaccination (beginning first dose primary series). median age among participants was 74 years; one participant immunocompromised. Of 10 with serology results, 9 (90%) had detectable Pan-Ig, IgG, IgA antibodies, 8 (80%) IgM antibodies. At antibody detection post-infection, two-thirds (6/9, 67%) were RT-PCR-positive, but none culture- positive. Ten received vaccination; all final observation ≤90 post-first dose. Post-vaccination geometric means IgG 10-200-fold higher than post-infection. Nursing this cohort mounted robust post-vaccination. augmented potential indicators enhanced protection that may confer on previously infected
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (43)
CITATIONS (0)